Company: SHPH
Filing Date: 2025-11-28
Form Type: 8-K
Source: 0001493152-25-025430
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-11-28
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers

On
November 21, 2025, Timothy Lorber resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (the “ Company”),
effective immediately. In connection with Mr. Lorber’s resignation, Mr. Lorber and the Company entered into a Separation Agreement
and Mutual Release (the “ Agreement”).

Pursuant
to the Agreement, Mr. Lorber will continue to provide part-time services at 50% of his base salary through December 4, 2025, to assist
with matters related to the transition of his job duties, and thereafter shall remain available for reasonable consultation and inquiries
through February 8, 2026. In consideration for his continued service and transition assistance, Mr. Lorber will receive a retention bonus
of $20,000 on November 21, 2025, and an additional $10,000 on December 4, 2025, subject to applicable taxes and withholdings. The Agreement
further provides that, on February 8, 2026, a total of 39,854 unvested restricted stock units previously granted to Mr. Lober will vest
in their entirety, contingent upon his fulfillment of the transition plan. Both the Company and Mr. Lorber have agreed to a mutual release
of claims, subject to certain exclusions as set forth in the Agreement. The Agreement also includes customary provisions regarding confidentiality,
non-disparagement, cooperation, and the return of Company property.

Effective
November 21, 2025, Christopher Cooper, who currently serves as Interim Chief Executive Officer, assumed the role of Chief Financial Officer
(Principal Financial Officer). Mr. Cooper will serve in this capacity while the Company conducts a search for a permanent Chief Financial
Officer.

A
copy of the Agreement reflecting the benefits that Mr. Lorber will receive, including the benefits described herein, is attached hereto
as Exhibit 10.1. The above description of the material terms of the Agreement does not purport to be complete and is qualified in its
entirety by reference to such Exhibit.